Freenome Stock

freenome.comHealthcare / BioTech & PharmaFounded: 2014Funding to Date: $2.46B

Freenome is a biotechnology company driven to provide the tools needed to detect, treat and prevent cancer using routing blood draw. This company was founded in 2014 by Gabe Otte, Riley Ennis, Charles Roberts and is headquartered in South San Francisco, CA. Freenome combines molecular biology with advanced computational biology and machine learning to help with early cancer detection.

Register To Buy and Sell Private Company Shares

For more details on private stock price information, financing and valuation for Freenome, register or login.
Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

Freenome Stock Price

Forge Price 1
Price not yet available
Last Closed Trade 2
Close Date
xx/xx/xx
Last Closed Trade Price
$xx.xx
Last Funding Round (LFR)
Date
xx/xx/xx
Price per Share
$xx.xx

Freenome Funding Rounds and Valuation

Funding History Chart
Funding Round Details
Funding Date Share Class Amount Raised Price per Share Post-Money Valuation Key Investors
02/15/2024 Series F $254MM $xx.xx $2.17B Andreessen Horowitz, Ark Investments, Arrowmark Partners, Artis Ventures, Bain Capital Life Sciences, Brightedge Ventures, Cormorant Capital, Dcvc, Eventide Asset Management Llc, Intermountain Ventures, Perceptive Advisors, Polaris Partners, Pura Vida Investments, Quest Diagnostics, Ra Capital Management, Roche, Sands Capital, Section 32, Squarepoint Capital, T. Rowe Price Associates
Price per Share
$xx.xx
Shares Outstanding
34,330,819
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Andreessen Horowitz, Ark Investments, Arrowmark Partners, Artis Ventures, Bain Capital Life Sciences, Brightedge Ventures, Cormorant Capital, Dcvc, Eventide Asset Management Llc, Intermountain Ventures, Perceptive Advisors, Polaris Partners, Pura Vida Investments, Quest Diagnostics, Ra Capital Management, Roche, Sands Capital, Section 32, Squarepoint Capital, T. Rowe Price Associates
01/11/2022 Series E $290MM $xx.xx $2.74B Roche
Price per Share
$xx.xx
Shares Outstanding
24,856,432
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.1x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Roche
12/07/2021 Series D $300MM $xx.xx $1.43B Andreessen Horowitz, Artis Ventures, Bain Capital, Brightedge Ventures, Catalio Capital Management, Cormorant Capital, Dcvc, Farallon Capital Management, Fidelity, Gv, Janus Henderson Investors, Kaiser Permanente, Novartis, Perceptive Advisors, Polaris Partners, Ra Capital Management, Ridgeback Capital Management, Roche Venture Fund, Rock Springs Capital, Sands Capital, Section 32, Soleus Capital Management, T. Rowe Price Associates
Price per Share
$xx.xx
Shares Outstanding
39,775,664
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Andreessen Horowitz, Artis Ventures, Bain Capital, Brightedge Ventures, Catalio Capital Management, Cormorant Capital, Dcvc, Farallon Capital Management, Fidelity, Gv, Janus Henderson Investors, Kaiser Permanente, Novartis, Perceptive Advisors, Polaris Partners, Ra Capital Management, Ridgeback Capital Management, Roche Venture Fund, Rock Springs Capital, Sands Capital, Section 32, Soleus Capital Management, T. Rowe Price Associates
08/26/2020 Series C $270MM $xx.xx $927.08MM American Cancer Society�S Brightedge Ventures, Andreessen Horowitz, Bain Capital, Catalio Capital Management, Colorectal Cancer Alliance, Cormorant Asset Management, Dcvc, Ecor1 Capital, Farallon Capital Management, Fidelity, Gv (Formerly Google Ventures), Janus Henderson Investors, Kaiser Permanente Ventures, Novartis, Perceptive Advisors, Polaris Partners, Ra Capital Management, Roche Venture Fund, Rock Springs Capital, Sands Capital, Section 32, Soleus Capital, T. Rowe Price Associates
Price per Share
$xx.xx
Shares Outstanding
40,826,799
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
American Cancer Society�S Brightedge Ventures, Andreessen Horowitz, Bain Capital, Catalio Capital Management, Colorectal Cancer Alliance, Cormorant Asset Management, Dcvc, Ecor1 Capital, Farallon Capital Management, Fidelity, Gv (Formerly Google Ventures), Janus Henderson Investors, Kaiser Permanente Ventures, Novartis, Perceptive Advisors, Polaris Partners, Ra Capital Management, Roche Venture Fund, Rock Springs Capital, Sands Capital, Section 32, Soleus Capital, T. Rowe Price Associates
07/24/2019 Series B $165MM $xx.xx $464.3MM Andreessen Horowitz, Brightedge Ventures, Data Collective Venture Capital, Gv, Kaiser Permanente Ventures, Perceptive Advisors, Polaris Partners, Ra Capital Management, Roche Venture Fund, Section 32, T. Rowe Price Associates, Verily Life Sciences
Price per Share
$xx.xx
Shares Outstanding
36,207,457
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Andreessen Horowitz, Brightedge Ventures, Data Collective Venture Capital, Gv, Kaiser Permanente Ventures, Perceptive Advisors, Polaris Partners, Ra Capital Management, Roche Venture Fund, Section 32, T. Rowe Price Associates, Verily Life Sciences
08/28/2017 Series A $69.62MM $xx.xx $196.16MM Allen & Company, Ame Cloud Ventures, Anne Wojcicki, Asset Management Ventures, Charles River Ventures, Data Collective, Founders Fund, Gv, Innovation Endeavors, Polaris Partners, Section 32, Spectrum 28
Price per Share
$xx.xx
Shares Outstanding
22,660,320
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Allen & Company, Ame Cloud Ventures, Anne Wojcicki, Asset Management Ventures, Charles River Ventures, Data Collective, Founders Fund, Gv, Innovation Endeavors, Polaris Partners, Section 32, Spectrum 28
06/19/2016 Series Seed-2 $5.55MM $xx.xx $25.34MM Andreessen Horowitz, Data Collective, Founders Fund, Third Kind Venture Capital
Price per Share
$xx.xx
Shares Outstanding
9,092,395
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Andreessen Horowitz, Data Collective, Founders Fund, Third Kind Venture Capital
05/06/2016 Series Seed-1 $800,016.00 $xx.xx $2.67MM Undisclosed Investors
Price per Share
$xx.xx
Shares Outstanding
3,360,000
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
6.0%
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
--
Key Investors
Undisclosed Investors

Freenome Investors Also Invested in These Private Companies

Colorectal Cancer Alliance
Ark Investments
Asset Management Ventures
Soleus Capital Management
Eventide Asset Management Llc
Ridgeback Capital Management
Cormorant Capital
Squarepoint Capital
Intermountain Ventures
Brightedge
Brightedge Ventures
Quest Diagnostics
Data Collective Venture Capital
Verily Life Sciences
American Cancer Society�S Brightedge Ventures
Gv (Formerly Google Ventures)

Leadership & Board

Leadership

Charles Roberts
Co-Founder & Chief Growth Officer
Mike Nolan
Chief Executive Officer
Julie Tran
Chief People Officer
Michael Ash
Chief Commercial Officer
Charles Roberts
Chief Growth Officer
Gregory Chow
Chief Financial Officer
Cheng-Ho Jimmy Lin Ph.D
Chief Scientific Officer
Lance Baldo MD
Chief Medical Officer

Board

Amy Raimundo
Kaiser Permanente Ventures
Dror Berman
Innovation Endeavors
Ellen Hukkelhoven Ph.D
Perceptive Advisors
Michael Krepps
BrightEdge.
Peter Kolchinsky Ph.D
RA Capital Management

Freenome stock FAQs

plusminus

Can you buy Freenome stock?

As Freenome is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private companies like Freenome, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to buy private market stock. If you are not accredited, find out how to begin the process and qualify for new investment opportunities.
plusminus

How to buy Freenome stock?

To invest in a private company like Freenome through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)

  1. Create a free account to access Forge’s marketplace.
  2. Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
  3. Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.
plusminus

Can you sell Freenome stock?

Yes, you may sell the Freenome stock you currently own. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company’s interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.
plusminus

How to sell Freenome stock?

If you hold private company shares of Freenome – whether as an employee or an early investor – Forge can help you sell them.

  1. Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
  2. Indicate your interest to sell your Freenome on our platform.
  3. Work with your dedicated Private Market Specialist who’ll help guide you through every step of the transaction.
plusminus

Is Freenome a public company?

No, Freenome is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.
plusminus

What is Freenome’s stock price?

Freenome is a privately held company and therefore does not have a public stock price. However, you may access Freenome private market stock price with Forge Data.
plusminus

What is Freenome’s stock ticker symbol?

Freenome does not have an official ticker symbol because this company is not currently publicly traded.
plusminus

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.

Freenome News and Media Highlights

Freenome swings $254m investment

To advance early cancer detection technology, Freenome received a fresh $254 million investment.

Freenome Raises $254 Million in New Funding to Accelerate its Platform for Early Cancer Detection

In a funding led by a16z Life Sciences Growth Fund, Freenome raised $254 million for its cancer detection platform.

Roche leads Freenome's $254M funding round for cancer-detecting blood tests

In early 2022, Freenome surpassed $1 billion in lifetime financing after raking in two nine-figure funding rounds barely a month apart, with plans to use the money to launch new studies of its cancer blood tests. Two years later, the company is adding to its coffers once again, with an eye toward both keeping those studies afloat and continuing to develop additional disease-detecting liquid biopsy tests. The latest funding round weighed in at $254 million, Freenome announced Thursday. It was led by Roche, which has participated in all of Freenome’s previous fundraising sessions and was also responsible for the $290 million contribution at the start of 2022 that brought Freenome’s total past the $1 billion mark.

Walgreens and Freenome Partner to Increase Diversity in Research Focused on the Early Detection of Cancer

Walgreens and biotech firm Freenome have announced a multi-year partnership to advance clinical studies of Freenome's blood-based tests for early cancer detection. Walgreens will use its national footprint and patient insights to engage diverse patient populations in Freenome's multi-cancer research program. The partnership will also work on building risk-prediction models and population health software to help identify people eligible for standard-of-care cancer detection testing.
Browse Insights
Updated on: Dec 21, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

1. Forge Price™ is a custom data-point calculated and disseminated by Forge Data LLC (“Forge Data”) and is a mark of Forge Data. Forge Price may rely on a very limited number of inputs in its calculation. Forge Price is prepared and disseminated solely for informational purposes. Redistribution is permitted solely with Forge’s written consent. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of Forge Price, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of Forge Price. Forge Price is derived from secondary activity on the Forge platform and other private market trading platforms, and other publicly-available datapoints collected by Forge.  Forge Price is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Neither reference to company names, nor calculation of Forge Price for a specific company, implies any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

2. The Last Closed Trade price displayed reflects the price at which the last trade in this company's security occurred on Forge, and can include secondary trades in any class of the company's security, or trades in units of funds holding the company's securities (the economics of which differ versus direct company ownership). The date displayed reflects the date on which the last trade in this company's security closed on Forge. This may be several weeks after the terms of the trade were agreed upon between the buyer and seller. In case of multiple trades closed on the same date, the price displayed is of either (i) the trade which terms were agreed upon most recently; or (ii) the trade with the higher notional value.

‘Stock Price’ or other private company metrics (‘PC Data’) may rely on a very limited number of trade and/or IOI inputs in their calculation. PC Data is prepared and disseminated solely for informational purposes. While Forge has obtained information from sources it believes to be reliable, Forge does not perform an audit or undertake any duty of due diligence or independent verification of any information it receives. Forge does not guarantee the accuracy, completeness, timeliness, or availability of PC Data, and are not responsible for any errors or omissions, regardless of the cause, or any results obtained from the use of PC Data. PC Data is derived from the performance and pricing of secondary activity on the Forge platform and other private market trading platforms. PC Data is not intended to, and does not necessarily, represent the market price of any securities (I.e., the price at which you could buy or sell such securities). Reference to company names does not imply any affiliation between Forge and that company, any endorsement or sponsorship by Forge of any company or vice versa, or any partnership, joint venture or other commercial relationship between Forge and any company. Rights with respect to any company marks referred to herein are owned by the company.

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.

Investing in private company securities is not suitable for all investors, is highly speculative, is high risk, and investors should be prepared to withstand a total loss of their investment. Private company securities are highly illiquid and there is no guarantee that a market will develop for such securities. Each investment carries its own risks, and investors should conduct their own due diligence regarding the investment, including obtaining independent professional advice. Past performance is not indicative of future results. This is not a recommendation, offer, solicitation of an offer, or advice to buy or sell securities by Forge, nor an offer of brokerage services in any jurisdiction where Forge is not permitted to offer brokerage services. Brokerage products and services are offered by Forge Securities LLC, a registered broker-dealer and member FINRA/SIPC. Please see other important disclaimers, disclosures and restrictions you acknowledge by using this website and to which you are subject.